Latest news
DSMB approves dose escalation in PepGen’s FREEDOM2-DM1 study - YahooYahoo · Fri, 07 Aug 2026 10:38:11 GMTClearmind Medicine (Nasdaq: CMND) wins DSMB nod to advance AUD trial - Stock TitanStock Titan · Thu, 06 Aug 2026 20:01:03 GMTPepGen to Advance PGN-EDODM1 Into Highest Dose Cohort in Phase 2 FREEDOM2-DM1 Study Following DSMB Review - BioSpaceBioSpace · Thu, 06 Aug 2026 12:39:14 GMTClearmind Reaches Key Clinical Trial Milestone as DSMB Unanimously Clears Progression in AUD Study - The Manila TimesThe Manila Times · Thu, 06 Aug 2026 12:21:58 GMTCMND-100 Set to Enter Human Testing for Moderate-to-Severe Alcohol Use Disorder - Stock TitanStock Titan · Thu, 06 Aug 2026 12:00:00 GMTClearmind advances CMND-100 alcohol use disorder trial into patient testing after Phase I safety readout - BitgetBitget · Thu, 06 Aug 2026 05:26:57 GMT